First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical trial NCT06217822 · RECRUITING

Trial details

NCT number: NCT06217822
Sponsor: Bayer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Metastatic Castration-resistant Prostate Cancer Prostate Specific Membrane Antigen (PSMA) Expression

Start date: 2024-03-07
Primary completion: 2028-11-26
Enrollment: 198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.